To quote Hannah Montana: Everyone makes mistakes. But when it comes to a cancer diagnosis, that’s something a provider can’t afford to make.

Boston Cell Standards (BCS), a biotechnology company Seshi Sompuram, Steven Bogen, and Kodela Vani co-founded in 2003, wants to modernize the way pathologists diagnose diseases such as breast cancer, colon cancer, and lung cancer.

When a doctor believes a patient may have cancer, they often perform a biopsy. In the lab, that tissue is stained. A pathologist needs to evaluate the color’s pigmentation on a scale from zero (light brown) to 3+ (dark brown). The darker the color, the more cancerous the tissue is. This process is called immunohistochemistry (IHC) testing, and relies on a judgment call rather than numeric standards.

Keep reading here.—AM

Training for a skill you’ve already mastered doesn’t just waste time and resources—it hinders overall career development and growth. That’s why HealthStream created an award-winning, personalized competency development program to bridge the gaps.

The Competency Suite+ pinpoints individual needs and development areas throughout every stage of clinicians’ careers. It offers critical judgment assessments designed to fill knowledge gaps with personalized recs powered by AI.

There are even role-specific development paths for over 35 different specialties and settings. No matter what career level or role a clinician is in, the Competency Suite+ has courseware and content to support them.

Don’t waste time and $$$ on generalized training. Learn more about precise, personalized development in HealthStream’s webinar or by booking a demo.

The Biden administration plans to reclassify cannabis as a Schedule III drug, paving the way for pharmaceutical companies to sell and distribute medical cannabis, NBC News reported this week.

The move would be the first reclassification of cannabis since the passage of the Controlled Substances Act in 1970, per NBC News. Downgrading cannabis to Schedule III from Schedule I (which is the strictest classification and includes drugs like heroin and methamphetamines) means the federal government acknowledges that cannabis has potential medical benefits.

The rescheduling would “open up the ability to actually test [cannabis] and put it in a laboratory without all of the restrictive measures” that a Schedule I drug faces, James Cole, who served as President Obama’s deputy attorney general and now sits on the National Cannabis Roundtable, told NBC News.

Keep reading here.—MA

Do you work in healthcare or have information about the industry that we should know? Email Maia at [email protected]. For confidential conversations, ask Maia for her number on Signal.

Perhaps it’s no surprise that a former chief information security officer like Jim Foote, now CEO of biotech startup First Ascent Biomedical, compares cybercriminals to cancer.

“They’re parasitic. They want to evade detection. They’re constantly evolving. They’re constantly changing their tactics,” Foote told IT Brew.

Truly leaving the security world (and security lexicon) behind might be difficult. But don’t count Foote as one of the CISOs leaving the field amid the fatigue of liability chills or never-ending battles with cyber adversaries.

Foote’s transition from malware to medicine is far more personal. In 2006, Foote’s son Trey, diagnosed with bone cancer, died at the age of 16, leading his father to start the Trey Foote Foundation and ultimately shift to a new career—one that has at least a few helpful echoes of his IT days.

Keep reading at IT Brew.—BH

Breaking the cycle. There’s an urgent, unmet need for therapies that can halt or reverse the progression of chronic diseases—and FibroBiologics is hard at work attempting to create them. FibroBiologics is developing fibroblast and fibroblast-derived therapies to provide potential treatments and cures for chronic diseases. Learn more.